Preventive medicine - Revisiting Rose: Strategies for reducing coronary heart disease

British Medical Journal

Volumn 332, Issue 7542, 2006, Pages 659-662

  Manuel, Douglas G ^a   Lim, Jenny ^a   Tanuseputro, Peter ^a   Anderson, Geoffrey M ^b   Alter, David A ^a   Laupacis, Andreas ^a   Mustard, Cameron A ^c  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR WORK AND HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NOTE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; ADULT; AGED; CORONARY ARTERY DISEASE; HEALTH CARE POLICY; HYPERCHOLESTEROLEMIA; MIDDLE AGED; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS;

EID: 33645231298     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. Rose GA. The strategy of preventive medicine. Oxford: Oxford University Press, 1992.
2. Rose G. Sick individuals and sick populations. 1985. Bull World Health Organ 2001;79:990-6.
3. Liao Y, McGee DL, Cooper RS, Sutkowski MB. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J 1999;137:837-45.
4. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
5. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169:921-4.
6. National Cholesterol Education Program. Detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). Bethesda, MD: US Department of Health And Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2002.
7. New Zealand Guidelines Group. Assessment and management of cardiovascular risk. Wellington: NZGG, 2003. www.nzgg.org.nz/ guidelines/0035/CVD_Risk_Full. pdfwww.nzgg.org.nz (accessed 29 June 2004).
8. British Heart Foundation. Updated guidelines on cardiovascular disease risk assessment. London: BHF, 2005.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J1 et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
10. National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Lipid management guidelines-2001. Med J Aust 2001;l75(suppl):S57- 85.
11. MacLean DR, Petrasovits A, Nargundkar M, Connelly PW, MacLeod E, Edwards A, et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. CMAJ 1992;146:1969-74.
12. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet 2000;355:675-87.
13. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA project populations. Lancet 2000;355:688-700.
14. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25:484-91.
15. Shea S, Basch CE. A review of five major community-based cardiovascular disease prevention programs. II. Intervention strategies, evaluation methods, and results. Am J Health Promot 1990;4:279-87.
16. Vartiainen E, Heath G, Ford E. Assessing population-based programs to reduce blood cholesterol level and saturated fats. Int J Technol Assess Health Care 1991;7:315-26.
17. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
18. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart 2004;90:1065-6.
19. Heidenreich PA. Patient adherence: the next frontier in quality improvement. Am J Med 2004;117:130-2.
20. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
21. Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Mol 2003;19:1359-66.
22. National Advisory Committee on SARS and Public Health. Learning from SARS. Renewal of public health in Canada. Ottawa: Health Canada, 2004.